Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia
Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia: An Ambidirectional Patient-Control Cohort Study
To collect large-scale multimodal data, including genomic information, neuroimaging, neurophysiological measures, cognitive assessments, and clinical characteristics from stroke survivors and healthy controls.
This study aims to develop and validate an integrated prediction model for identifying individuals at high risk of post-stroke vascular dementia and to establish a foundation for precision medicine approaches in stroke-related cognitive impairment.
Přehled studie
Postavení
Podmínky
Detailní popis
This study aims to establish a comprehensive multimodal dataset integrating genomic information, clinical characteristics, neuroimaging, neurophysiological measures, and longitudinal cognitive assessments in stroke survivors and cognitively healthy controls. The study includes participants from the subacute to chronic stages after stroke and follows them longitudinally to capture changes in cognitive and functional outcomes over time.
By combining whole genome sequencing, magnetic resonance imaging (MRI), electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), and clinical assessments, the study seeks to characterize factors associated with cognitive decline and vascular dementia following stroke.
The collected data will be used to develop and validate an integrated multimodal prediction model capable of identifying individuals at elevated risk of post-stroke vascular dementia. The findings are expected to improve risk stratification, support individualized monitoring and intervention strategies, and contribute to the development of precision medicine approaches for stroke survivors.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Seyoung Shin, MD
- Telefonní číslo: +82437505000
- E-mail: seyoung0706@chamc.co.kr
Studijní místa
-
-
Gyeonggi-do
-
Gyeonggi-do, Gyeonggi-do, Jižní Korea, 13497
- Bundang CHA Medical Center
-
Kontakt:
- Seyoung Shin, MD
- Telefonní číslo: +82427305000
- E-mail: seyoung0706@chamc.ac.kr
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
Healthy Control Group:
- Adults aged 19 years or older.
- Able to be age- and sex-matched to the stroke cohort.
- No history of stroke, transient ischemic attack (TIA), or other central nervous system disorders.
- Cognitive function within the normal range for age and education level based on screening assessments (K-MMSE and K-MoCA).
- Able to understand the study procedures and provide written informed consent.
Stroke Patient Group:
- Adults aged 19 years or older.
- First-ever ischemic or hemorrhagic stroke confirmed by CT or MRI.
- Enrolled in one of the following strata according to time since stroke onset:
Stratum A: 7 days to 3 months after stroke onset. Stratum B: >3 months to 12 months after stroke onset. Stratum C: >12 months to 36 months after stroke onset.
- Able to understand the study procedures and provide written informed consent, or consent provided by a legally authorized representative when applicable.
Exclusion Criteria:
Healthy Control Group:
- Current severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications.
- Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL).
- Severe medical illness considered inappropriate for study participation.
- Any condition that, in the opinion of the investigator, would make participation unsuitable.
Stroke Patient Group:
- Impaired ability to provide consent (MMSE <10) without an accompanying caregiver or legally authorized representative.
- History of dementia due to causes other than stroke (e.g., Alzheimer's disease) prior to stroke onset.
- History of major neurological disorders affecting cognition prior to stroke onset (e.g., Parkinson's disease, brain tumor, multiple sclerosis).
- Severe aphasia or impaired consciousness preventing completion of cognitive assessments.
- Current or pre-stroke severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications.
- Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL).
- Contraindication to MRI (e.g., metallic implants) or refusal to provide blood samples for genomic analysis.
- Any condition that, in the opinion of the investigator, would make participation unsuitable.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
Stroke patients
Adults aged 19 years or older with first-ever ischemic or hemorrhagic stroke.
Participants may be enrolled during the subacute or chronic stage after stroke and will undergo genomic, neuroimaging, neurophysiological, cognitive, and functional assessments with longitudinal follow-up for up to 36 months.
|
|
Healthy controls
Cognitively normal adults aged 19 years or older without a history of stroke, transient ischemic attack, or other major central nervous system disorders.
Participants will undergo genomic, neuroimaging, neurophysiological, cognitive, and functional assessments and follow-up evaluations.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mini Mental Status Examination
Časové okno: Baseline to 36 months
|
Mini Mental State Examination is a 30-question assessment of cognitive function that evaluates attention and orientation, memory, registration, recall, calculation, language, and ability to draw a complex polygon (range 0-30).
Higher scores indicate better cognitive function.
|
Baseline to 36 months
|
|
Korean Montreal Cognitive Assessment
Časové okno: Baseline to 36 months
|
The Korean Montreal Cognitive Assessment is a cognitive screening tool designed to detect mild cognitive impairment.
It evaluates multiple cognitive domains including attention, executive function, memory, language, visuospatial ability, abstraction, calculation, and orientation (range 0-30).
Higher scores indicate better cognitive function.
|
Baseline to 36 months
|
|
Clinical Dementia Rating
Časové okno: Baseline to 36 months
|
The Clinical Dementia Rating is a clinician-rated scale used to assess the severity of cognitive impairment and dementia across six domains including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care (range 0-3).
Higher scores indicate greater cognitive impairment and worse outcomes.
|
Baseline to 36 months
|
|
Functional Ambulation Category
Časové okno: Baseline to 36 months
|
The Functional Ambulation Categories is a 5-point functional walking test that evaluates ambulation ability, determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device (range 0-5).
Higher scores indicate greater independence in ambulation.
|
Baseline to 36 months
|
|
Modified Barthel Index
Časové okno: Baseline to 36 months
|
The Modified Barthel Index is a scale used to measure disability or dependence in activities of daily living in stroke survivors (range 0-100).
Higher scores indicate greater independence in activities of daily living.
|
Baseline to 36 months
|
|
Berg Balance Scale
Časové okno: Baseline to 36 months
|
The Berg Balance Scale is a 14-item performance-based measure used to assess static and dynamic balance abilities and risk of falling in individuals with neurological disorders (range 0-56).
Higher scores indicate better balance performance and lower risk of falling.
|
Baseline to 36 months
|
|
Electroencephalography Delta-Alpha Ratio
Časové okno: Baseline to 36 months
|
The delta-alpha ratio (DAR) is a quantitative electroencephalographic measure calculated as delta power divided by alpha power.
Higher DAR values indicate greater electroencephalography slowing and are associated with impaired brain function.
|
Baseline to 36 months
|
|
Electroencephalography Functional Connectivity Index
Časové okno: Baseline to 36 months
|
Functional connectivity indices derived from electroencephalography recordings to assess connectivity between brain regions and overall brain network organization.
|
Baseline to 36 months
|
|
Functional Near-Infrared Spectroscopy (fNIRS)
Časové okno: Baseline to 36 months
|
Functional near-infrared spectroscopy is a non-invasive neuroimaging technique used to assess cortical activation by measuring changes in oxygenated and deoxygenated hemoglobin during task performance.
|
Baseline to 36 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2026-04-084
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .